stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
25.11
0.92
−3.53%
Follow CAI
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
90.19 | 47.41 | 0.00 | 0.00 |
+7 more quarters Free account |
P/S ratio |
8.30 | 5.09 | 5.57 | 9.38 | |
P/FCF ratio |
221.35 | 40.67 | 40.92 | 113.82 | |
P/Operating CF |
(390.89) | 177.02 | 153.67 | 170.04 | |
P/B ratio |
14.70 | 8.52 | 8.51 | 13.19 | |
Price to Tangible BV |
15.19 | 8.81 | 8.80 | 13.65 | |
EV/Sales |
7.91 | 4.69 | 5.08 | 8.86 | |
EV/EBITDA |
46.08 | 25.78 | 32.37 | 89.36 | |
EV/Operating CF |
98.89 | 27.53 | 31.28 | 86.50 | |
EV/FCF |
211.17 | 37.44 | 37.34 | 107.53 | |
Quick Ratio |
0.84 | 4.75 | 6.35 | 7.17 | |
Current Ratio |
6.71 | 5.53 | 7.05 | 7.85 | |
Net Debt/EBITDA |
0.00 | (11.85) | (34.07) | (4.51) | |
Debt/Assets |
31.32% | 31.97% | 32.83% | 33.67% | |
Debt/Equity |
0.00 | 0.66 | 0.64 | 0.66 | |
Asset Turnover |
0.94 | 0.91 | 1.56 | 1.44 | |
Operating CF/Net income |
(1.46) | (44.70) | (64.46) | 0.55 | |
Capex/Depreciation |
— | (3.23) | (1.34) | (1.04) | |
Interest Coverage |
2.09 | 2.92 | 0.41 | 7.79 | |
Research and Development Expense of Revenue |
12.29% | 12.27% | 14.49% | 10.87% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 45.62% | 48.46% | 34.37% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.02 | 0.02 | |
Share Based Compensation of Revenue |
6.72% | 8.43% | 7.34% | 4.56% | |
Graham Net Nets |
0.05 | 0.08 | 0.09 | 0.06 | |
Graham Number |
0.00 | 4.21 | 0.00 | 0.00 | |
Earnings Yield |
1.11% | 2.11% | (42.46%) | (41.36%) | |
Free Cash Flow Yield |
0.45% | 2.46% | 2.44% | 0.88% | |
Revenue per Share |
0.97 | 0.93 | 0.77 | 1.04 | |
Operating CF per Share |
(0.08) | 0.10 | 0.12 | 0.16 | |
Capex per Share |
0.00 | (0.08) | (0.04) | (0.02) | |
Free Cash Flow per Share |
(0.08) | 0.02 | 0.08 | 0.14 | |
Cash per Share |
0.00 | 2.80 | 2.91 | 2.84 | |
Shareholders Equity per Share |
0.00 | 2.09 | 2.10 | 2.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 2.09 | 2.10 | 2.05 | |
Free Cash Flow |
(22.25) | 6.40 | 22.53 | 39.69 | |
Working Capital |
908.32 | 866.39 | 870.28 | 870.66 | |
Capital Expenditures |
— | (22.07) | (10.34) | (5.09) | |
Net Current Asset Value |
451.13 | 419.94 | 445.28 | 449.44 | |
EV/EBIT |
59.28 | 30.28 | 42.55 | 159.45 | |
Capex to Sales |
0.00 | 0.08 | 0.05 | 0.02 | |
Price to Operating Income |
62.14 | 32.89 | 46.63 | 168.78 | |
| Other line items | |||||
Average Receivables |
80.01 | 83.89 | 89.38 | — | |
Average Payables |
46.42 | 57.36 | 48.80 | — | |
Average Inventory |
93.84 | 82.20 | 57.93 | — | |
Average Assets |
1,120.10 | 1,092.34 | 581.19 | 562.83 | |
Average Common Equity |
— | 522.32 | (952.67) | — |
Columns are period end dates · fundamentals updated 4 Nov 2026